PVH-CORP.
14.1.2022 07:02:03 CET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce Lalaland and UZURI K&Y as winners of the third Tommy Hilfiger Fashion Frontier Challenge, a dedicated global program designed to find and support ideas that lead to a more inclusive fashion landscape. The program’s final virtual event took place on January 12th-13th, where the six finalists pitched their concepts to a prestigious jury panel. The winners will share a prize fund of €200,000 and receive a year-long mentorship with internal experts from Tommy Hilfiger and from INSEAD — one of the world’s leading and largest graduate business schools. They also secured a place in an INSEAD program that brings people, cultures, and ideas together to cultivate innovative leaders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005825/en/
More than 430 startups and scaleups from 22 countries submitted their ideas in January 2021 for this initiative, which echoes Tommy Hilfiger's sustainability vision to Waste Nothing and Welcome All. This year's program particularly strived to amplify and support Black, Indigenous and People of Color (BIPOC) entrepreneurs who are working to advance their communities, while fostering a more inclusive future for the fashion industry. For the first time, fans of the TOMMY HILFIGER brand were able to participate in the initial phases of the challenge, where they cast their digital vote to help narrow down the applications to identify the finalists. Alongside Tommy Hilfiger associates at the final event, they were also invited to vote for their favorite pitch to award an additional €15,000 to one of the finalists.
“This empowering challenge brought together passionate and hard-working individuals with fresh ideas on how to create a future of fashion we can all look forward to,” said Tommy Hilfiger. “It was an impressive final event, and I am proud to continue this journey with the entrepreneurs who presented groundbreaking and impactful solutions that challenge how we think, build, and create.”
Lalaland, a Netherlands-based platform that uses artificial intelligence to generate customized and inclusive synthetic models of different ethnicities, was awarded €100,000. “Creating technology that drives a more inclusive and diverse e-commerce platform is at the heart of our vision at Lalaland,” said Michael Musandu, co-founder, and CEO of Lalaland. “Being part of the Tommy Hilfiger Fashion Frontier Challenge brought incredible insights and will elevate our A.I. solution to reach more people than we could have imagined. Through donning this achievement, our team cannot wait to empower a welcoming online shopping experience, so no consumer feels under-represented.”
UZURI K&Y , a Rwandan-based eco-friendly shoe brand that uses recycled car tires from sub-Saharan Africa and employs local youth, was also awarded €100,000. “We are honored to be named a winner of the Tommy Hilfiger Fashion Frontier Challenge,” said Kevine Kagirimpundu, co-founder, and CEO of UZURI K&Y. “This opportunity has provided mentorship, strategic guidance, and given us a platform to share our dream of bringing sustainable footwear options from Africa to the global market. We are dedicated to drive real impact and inspire the youth of today to craft a cleaner future.”
Clothes to Good, a South African-based social enterprise that creates micro-business opportunities and jobs for people with disabilities through textile recycling, was awarded €15,000. “We feel blessed to be recognized by the Tommy Hilfiger Fashion Frontier Challenge viewers, it’s an experience we will never forget,” said Tammy Greyling, Operations Director and Occupational Therapist at Clothes to Good. “It’s humbling to know others believe in our dream to really make a difference for people with disabilities and their families. Receiving this award will empower Clothes to Good to continue creating micro-business and job opportunities through textile recycling from the South African community."
The jurors who oversaw the Tommy Hilfiger Fashion Frontier Challenge final event included:
- Mr. Tommy Hilfiger
- Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe
- Yara Shahidi, award-winning actress, producer, and change agent
- Esther Verburg, EVP, Sustainable Business and Innovation, Tommy Hilfiger Global and PVH Europe
- Adrian Johnson, Entrepreneur, Adjunct Professor of Entrepreneurship, Technology and Media at INSEAD
- Katrin Ley, Managing Director of Fashion for Good and Founding Curator of the Amsterdam Global Shapers Hub
- Yvonne Bajela, founding member and principal at investment firm Impact X Capital
Applications for the fourth installment of the Tommy Hilfiger Fashion Frontier Challenge will open in March 2022. Entrepreneurs who are interested in receiving more information are invited to register here: https://platform.younoodle.com/competition/thffc_2022 .
Tommy Hilfiger’s mission is to become a leading sustainable designer lifestyle company that Wastes Nothing and Welcomes All, through how it creates its product, manages its operations and connects with its communities and stakeholders. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy, can be found on https://responsibility.pvh.com/tommy/ .
More information about the Tommy Hilfiger Fashion Frontier Challenge is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger and @TommyHilfiger.
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER
and TOMMY JEANS
, Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS
product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER
and TOMMY JEANS
brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER
and TOMMY JEANS
retail stores, leading specialty and department stores, select online retailers, and at tommy
.com.
About PVH Corp.
PVH is one of the world’s largest and most admired fashion companies, connecting with consumers in over 40 countries. Our global iconic brands include Calvin Klein
and TOMMY HILFIGER
. Our 140-year history is built on the strength of our brands, our team and our commitment to drive fashion forward for good. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005825/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
